Back to Search Start Over

Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival

Authors :
Kyung Seok Han
Eun Mi Hwang
Sung Joong Lee
Jinpyo Hong
Daniel J. Brat
Sung Hye Park
Chun Kee Chung
Hye Young Shin
C. Justin Lee
Eun Joo Roh
Bo Mi Ku
Jae Yong Park
Sun Ha Paek
Dong Ho Woo
Antoine G. Almonte
Yeon Kyung Lee
Sang Soo Kang
Seung Hyun Yoo
Stephen F. Traynelis
Source :
Cancer research. 70(3)
Publication Year :
2010

Abstract

Ca2+ signaling is an important determining factor in many cellular processes, especially in cancer cell proliferation, motility and invasion. Glioblastoma is the deadliest brain cancer with its average survival time of less than a year, with the most prominent cellular feature being the ability of these cells to migrate to and invade the neighboring tissue. We hypothesized that disturbing the Ca2+ signaling pathway would decrease the propensity for these cells to migrate. Thus, we investigated the detailed Ca2+ signaling pathway of the glioblastoma cells in response to various receptor tyrosine kinases (RTK) and G-protein coupled receptor (GPCR) agonists. Here we report that caffeine, which is a well-known activator of ryanodine receptors (RyRs), paradoxically inhibits inositol-1, 4, 5-triphospate receptor(IP3R)-mediated Ca2+ increase by selectively targeting IP3R subtype 3(IP3R3), whose mRNA expression is significantly increased in glioblastoma cells. Consequently, by inhibiting IP3R3-mediated Ca2+ release, caffeine was found to inhibit the invasion and migration of various glioblastoma cell lines in scrape motility, Matrigel invasion, soft agar, and brain slice implantation assays. In a mouse xenograft model of glioblastoma, caffeine intake via drinking water greatly increased mean survival duration of subject animals. These findings propose IP3R3 as a novel target for glioblastoma treatment and that caffeine may be a useful adjunct therapy that slows glioblastoma invasion and migration by selectively targeting IP3R3.

Details

ISSN :
15387445
Volume :
70
Issue :
3
Database :
OpenAIRE
Journal :
Cancer research
Accession number :
edsair.doi.dedup.....22804a09bae5222f54bd90aacdbf3418